StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 8 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows AMIX's percentile within the scored universe — observational ranking, not a recommendation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.32 | $0.32 | -1.22% | 0.1M |
| 05-19 | $0.27 | $0.28 | +5.04% | 29.9M |
| 05-20 | $0.28 | $0.34 | +18.49% | 4.5M |
| 05-21 | $0.33 | $0.40 | +22.21% | 1.1M |
| 05-22 | $0.41 | $0.40 | -2.16% | 1.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-14.30M | $-10.96M | $-3.42M | $-11.59M |
Net Income | $-14.05M | $-7.45M | $-3.34M | $-11.41M |
EPS (Diluted) | $-2.41 | $-2.53 | $-1.07 | $-6.46 |
Total Assets | $10.21M | $7.93M | $9.00M | $9.81M |
Total Liabilities | $1.65M | $1.49M | $1.97M | $1.71M |
Cash & Equivalents | $9.93M | $7.48M | $8.59M | $9.14M |
Free Cash Flow OCF − CapEx | $-9.40M | $-6.42M | $-2.60M | $-8.31M |
Shares Outstanding | 11.41M | 6.19M | 4.02M | 2.50M |
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.